Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8569329 | 0.81 | SIGMAR1 (0.67) | SIGMAR1 | |
| SCHEMBL24069471 | 0.76 | SIGMAR1 (0.54) | SIGMAR1CARM1PRMT6CCR3 | |
| SCHEMBL8091682 | 0.75 | SIGMAR1 (0.66) | SIGMAR1 | |
| SCHEMBL8091980 | 0.75 | SIGMAR1 (0.70) | SIGMAR1CCR3SLC6A3 | |
| SCHEMBL10867697 | 0.74 | SIGMAR1 (0.53) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL8092779 | 0.74 | SIGMAR1 (0.64) | SIGMAR1 | |
| SCHEMBL10685564 | 0.73 | SIGMAR1 (0.80) | SIGMAR1CCR3SLC6A3 | |
| SCHEMBL7449796 | 0.73 | SIGMAR1 (0.74) | SIGMAR1CARM1PRMT6CCR3 | |
| SCHEMBL5708589 | 0.73 | SIGMAR1 (0.73) | SIGMAR1CCR3 | |
| SCHEMBL5277741 | 0.73 | CCR3 (0.61) | CARM1PRMT6CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153722-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153722-A1 | CDK2/5 DEGRADERS AND USES THEREOF | CDK2, CDK5, CDK5R1 | SIGMAR1 4742/4885CARM1 1925/4885PRMT6 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.